RESOURCES

Where research scientists come to find up to date resources on antibody discovery against challenging membrane protein targets.

Category: news

Integral Molecular Receives NIAID Award to Combat COVID-19

PHILADELPHIA – The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Integral Molecular $1 million to enable the application of Integral Molecular’s technology platforms to aid in the discovery of vaccines and therapeutics to combat COVID-19.

Integral Molecular’s Shotgun Mutagenesis Epitope Mapping platform precisely identifies where antibodies bind to their target proteins, and will be used to design an improved vaccine and to identify the best therapeutic antibody candidates and combination cocktails.

SARS-CoV-2 Reporter Virus Particles are safe and non-replicating virus particles that display the coronavirus spike protein, the major viral protein targeted by the immune system. Reporter viruses provide developers an alternative to using live infectious virus, allowing antibodies, therapeutic drugs, and serum from vaccinated patients to be rapidly tested under safe laboratory conditions.

The company will use its Membrane Proteome Array platform of 6,000 human proteins to identify additional proteins that allow the virus to invade cells, helping to explain how the virus has been able to spread so quickly. The company’s Membrane Proteome Array platform has already been used to identify multiple receptors used by other viruses.

“We are pleased to support the scientific community around the world with our expertise and technologies in response to this pandemic,” said Benjamin Doranz, President and CEO of Integral Molecular. “We are fortunate to have financial support from NIAID to rapidly develop a suite of reagents and solutions that will make an impact on the speed of vaccine development and therapeutic testing.”

Integral Molecular has similarly responded to previous epidemics, including Zika, Ebola, and Chikungunya viruses. Since 2009, Integral has been awarded three consecutive contracts by NIAID to study viral immune responses, publishing over 50 virus-related publications including in high profile journals such as Cell and Nature.

This project has been funded by NIAID/NIH under Contract 75N93019C00073.

About Integral Molecular

Integral Molecular (www.integralmolecular.com) is the industry leader in discovering and characterizing therapeutic antibodies against membrane proteins, an important group of drug targets found on the surfaces of cells and viruses. Integral Molecular’s technologies have been integrated into the drug discovery pipelines of over 300 biotech and pharmaceutical companies to help discover new therapies for cancer, diabetes, auto-immune disorders and viral threats such as SARS-CoV-2, Ebola, Zika, and dengue.

Press Contact:
Integral Molecular Inc,
Soma Banik, PhD, Director of Communications
215-966-6061
info@integralmolecular.com
www.integralmolecular.com

Integral Molecular Accelerates Coronavirus Vaccine Research

PHILADELPHIA –Integral Molecular announces the mobilization of two of its key technology platforms to aid in the discovery of vaccines and therapeutics against the novel coronavirus which causes COVID-19. The company will use Shotgun Mutagenesis Epitope Mapping and the Membrane Proteome Array to understand the human immune response to the virus and identify cellular receptors that explain how the virus has been able to spread so quickly.

Integral Molecular has similarly responded to previous emerging epidemics, including Zika, Ebola and Chikungunya viruses, supporting vaccine and therapeutic discovery efforts throughout industry and academia. The company’s Shotgun Mutagenesis Epitope Mapping technology has been used to map over 1,000 antibody binding sites and is used throughout the vaccine industry. The company’s Membrane Proteome Array platform has already been used to identify multiple receptors used by viruses to enter and infect cells.

“Deep expertise in virology is at the core of Integral Molecular’s nearly 20-year history, including our contributions to discovering the receptor for HIV and other viruses,” said Benjamin Doranz, President of Integral Molecular. “We have the ability to use our unique tools to help curb the spread of this deadly virus and have initiated research efforts on multiple fronts to aid in the global effort for a coronavirus vaccine.”

About Integral Molecular

Integral Molecular (www.integralmolecular.com) is the industry leader in epitope mapping and antibody discovery, with a pipeline of therapeutic antibodies against GPCRs, ion channels, transporters, and immuno-oncology targets. Built on the company’s extensive experience optimizing membrane proteins, Integral Molecular’s technology suite enables the isolation, characterization, and engineering of MAbs against otherwise intractable targets. The company currently has therapeutic programs focused on cancer, pain, immunity, and metabolic diseases

Press Contact:
Integral Molecular Inc,
Soma Banik, PhD, Director of Communications
215-966-6061
info@integralmolecular.com
www.integralmolecular.com

Integral Molecular Launches ReadyMap Services for Rapid, Conformational Epitope Mapping

PHILADELPHIA –Integral Molecular, the industry leader in the discovery and characterization of antibodies against membrane proteins, announces the launch of ReadyMap services, an expansion of its Shotgun Mutagenesis Epitope Mapping platform for rapid mapping of antibody binding sites on pre-validated protein targets.

Epitope mapping enhances antibody intellectual property and enables informed lead selection for antibodies by revealing their mechanisms of action. With its 4-week turnaround time, ReadyMap services allow conformational epitope mapping to be used early in the antibody discovery process for lead selection.

Integral Molecular’s first ReadyMap alanine-scan libraries address the needs of cancer researchers working on HER2, HER3, and PD-L1. Integral Molecular also continues to offer custom Shotgun Mutagenesis epitope mapping services for any protein target.

Integral Molecular is a trusted partner to numerous companies as well as the NIH, mapping over 1,000 epitopes with a 95% success rate. Shotgun Mutagenesis epitope mapping data have been featured in over 40 patents and 100 publications, many in high-profile journals such as Cell, Nature and PNAS.

“Our epitope mapping technology has been instrumental in the detailed characterization and protection of antibody assets,” said Sharon Willis, VP of Sales and Customer Relations. “We understand that our customers benefit from faster epitope data to inform antibody selection, and our ReadyMap services provide this, even for conformational antibodies and difficult targets.”

About Integral Molecular

Integral Molecular (www.integralmolecular.com) is the industry leader in epitope mapping and antibody discovery, with a pipeline of therapeutic antibodies against GPCRs, ion channels, transporters, and immuno-oncology targets. Built on the company’s extensive experience optimizing membrane proteins, Integral Molecular’s technology suite enables the isolation, characterization, and engineering of MAbs against otherwise intractable targets. The company currently has therapeutic programs focused on cancer, pain, immunity, and metabolic diseases

Press Contact:
Integral Molecular Inc,
Soma Banik, PhD, Director of Communications
215-966-6061
info@integralmolecular.com
www.integralmolecular.com

Integral Molecular Announces Preclinical P2X7 Antibody Assets for Autoimmune Disorders

PHILADELPHIA – Integral Molecular, the leader in discovering antibodies against multipass membrane proteins, announces lead monoclonal antibodies (MAbs) against P2X7, a structurally complex ion channel that is the target for autoimmune disorders including atopic dermatitis and glomerulonephritis. The panel of P2X7 antibodies is fully humanized and optimized, and ready to progress towards preclinical studies.

The P2X7 ion channel target is involved in regulating a population of T cells that drive multiple autoimmune diseases. However, the target has been largely refractory to antibody discovery efforts due to its complex structure.

“Despite its important role in the pathway of many diseases, there are no existing drugs against P2X7,” said Ross Chambers, VP of Antibody Discovery. “Our MPS Antibody Discovery platform was built to handle complex membrane protein targets such as P2X7 and has enabled us to isolate high-affinity antibodies in the picomolar range that exhibit antagonist or rare agonist activity.“

Integral Molecular’s MPS Antibody Discovery platform encompasses a comprehensive technology suite that overcomes the obstacles of working with highly conserved and structurally complex membrane protein targets, including antigen engineering and presentation on Lipoparticles, immunization of divergent species, and deep screening techniques such as B-cell cloning to recover rare antibodies.

Integral Molecular will discuss its antibody assets in immune modulation, oncology, and metabolic disease at the upcoming JP Morgan Conference taking place from January 13-16, 2020 in San Francisco, California. The company is currently isolating MAbs against dozens of membrane protein targets and welcomes antibody out licensing opportunities and discovery partnerships.

About Integral Molecular
Integral Molecular (www.integralmolecular.com) is the industry leader in epitope mapping and antibody discovery, with a pipeline of therapeutic antibodies against GPCRs, ion channels, transporters, and immuno-oncology targets. Built on the company’s extensive experience optimizing membrane proteins, Integral Molecular’s technology suite enables the isolation, characterization, and engineering of MAbs against otherwise intractable targets. The company currently has therapeutic programs focused on cancer, pain, immunity, and metabolic diseases.

Contact:
Integral Molecular, Inc.
Soma Banik
Director of Scientific Communications
215-966-6061
info@integralmolecular.com

Integral Molecular to Advance Vaccine Discovery with NIH Contract for $5.5M

PHILADELPHIA – (PR NEWSWIRE) – The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Integral Molecular a contract (75N93019C00073) which will provide up to $5.5M over the next five years to define antibody responses to pathogenic viruses including Zika, Marburg and equine encephalitis viruses (EEV), aiding the discovery of vaccines and therapeutics against these currently untreatable and often lethal viruses.

With this third competitive contract award, NIAID, part of the National Institutes of Health (NIH), has recognized Integral Molecular’s achievements in using epitope mapping to understand the human immune response to viruses. This research is being conducted in collaboration with Dr. James Crowe, Director of the Vanderbilt Vaccine Center.

“Our nearly 20 year experience studying pathogenic viruses including Dengue, Chikungunya, Hepatitis C, Zika, and Ebola has expanded our understanding of how antibodies can provide protection from viruses” said Benjamin Doranz, CEO of Integral Molecular and Principal Investigator of the contract. “This continued support from NIAID validates our approach, allows us to broaden the scope of our studies, and will yield new insights that provide effective therapeutics and vaccines against these deadly viruses.”

Integral Molecular’s Shotgun Mutagenesis epitope mapping technology has provided powerful insights that have contributed to over 40 manuscripts in high impact journals including Cell, Nature and Immunity. Shotgun Mutagenesis epitope mapping has been used to map over 1,000 antibody binding sites to generate mechanistic insights and intellectual property, and is used throughout the vaccine industry.

About Integral Molecular
Integral Molecular (www.integralmolecular.com) is the industry leader in epitope mapping and antibody discovery, with a pipeline of therapeutic antibodies against GPCRs, ion channels, transporters, and immuno-oncology targets. Built on the company’s extensive experience optimizing membrane proteins, Integral Molecular’s technology suite enables the isolation, characterization, and engineering of MAbs against otherwise intractable targets. The company currently has therapeutic programs focused on cancer, pain, immunity, and metabolic diseases.

Contact:
Integral Molecular, Inc.
Soma Banik
Director of Scientific Communications
215-966-6061
info@integralmolecular.com

Philadelphia’s Integral Molecular Opens New Research Center in Response to Upsurge in Antibody Discovery Partnerships

PHILADELPHIA – (PR NEWSWIRE) – Integral Molecular, the industry leader in membrane protein solutions, has expanded its research facility to a second location to accommodate an upsurge in MPS Antibody Discovery partnerships and the progression of its internal therapeutic antibody pipeline. The new state-of-the-art laboratory space houses specialized equipment including high-throughput robotics and microfluidic biosensors to support the isolation of therapeutic antibodies.

Philadelphia Mayor Jim Kenney was present yesterday at the opening of Integral Molecular’s new facility to represent the city’s commitment to biotechnology and innovation. “We are thrilled to see Integral Molecular’s expansion and continued success in Philadelphia,” said Mayor Kenney. “Integral Molecular’s growth represents the extraordinary innovation, job creation, and retention of talent in the vibrant and flourishing University City biotechnology hub.”

Integral Molecular’s second research facility more than doubles its footprint in Philadelphia’s uCity Square. University City Science Center Senior Vice President Curt Hess calls Integral Molecular “A poster-child success story of the Science Center.” He continues, “We are proud to have supported Integral Molecular from its inception as a two-person company in our incubator through major milestones like its recent expansion. It is interesting to note that Integral Molecular now occupies the laboratory space where Centocor (now part of Janssen Biotech) originated and will carry on the legacy of the successes built in our community.”

Integral Molecular’s success is based on its innovative approaches in the field of antibody discovery against membrane protein targets. “Our technologies have been recognized as providing an unprecedented success rate of over 95%, generating antibodies against the most difficult targets,” said Benjamin Doranz, President of Integral Molecular. In the past year, Integral Molecular has entered research partnerships with numerous companies, including Merus N.V., Ono Pharmaceutical, and Daiichi Sankyo, who are leveraging the MPS Antibody Discovery Platform to obtain antibodies against hard to treat diseases.

About Integral Molecular

Integral Molecular (www.integralmolecular.com) is the industry leader in membrane protein solutions, with a pipeline of therapeutic antibodies against GPCRs, ion channels, transporters, and immuno-oncology targets. Built on the company’s extensive experience optimizing membrane proteins, Integral Molecular’s technology suite enables the isolation, characterization, and engineering of MAbs against otherwise intractable targets. The company currently has therapeutic programs focused on cancer, pain, immunity, and metabolic diseases.

Contact:
Integral Molecular, Inc.
Soma Banik
Director of Scientific Communications
215-966-6061
info@integralmolecular.com

Integral Molecular Selected as the First Industry Partner in The Wistar Institute’s Biomedical Research Technician Apprenticeship

PHILADELPHIA ¬ Sept. 26, 2019 — Integral Molecular, Inc. has been selected by The Wistar Institute, a global leader in cancer, immunology and infectious disease research as the first industry partner for its Biomedical Research Technician (BRT) Apprenticeship. This relationship continues Integral Molecular’s dedication to community partnership, economic development, and job creation in Philadelphia.

Wistar’s BRT Apprenticeship, the first-ever registered, nontraditional apprenticeship program for biomedical research ratified by the Pennsylvania Department of Labor & Industry, offers a pathway to fill in-demand jobs within Philadelphia’s fast-growing biotechnology industry. This extends Wistar’s Biomedical Technician Training Program, which helps students from the Community College of Philadelphia gain valuable hands-on laboratory experience and jobs in the life sciences.

“For the past two years, Wistar’s BRT Apprenticeship has fostered the next generation of biomedical researchers in Philadelphia by creating a career pathway,” said William Wunner, Ph.D., director of Academic Affairs and director of Outreach Education and Technology Training at Wistar. “With its focus on cutting-edge antibody technologies, Integral Molecular is the ideal setting for students to acquire marketable skills in the biotechnology industry.”

Wistar’s non-traditional BRT Apprenticeship is supported by Philadelphia Works, Inc., the city’s Workforce Development Board, under the governance of the Pennsylvania Department of Labor & Industry. Learn more: wistar.org/education-training

About Integral Molecular
Integral Molecular is the industry leader in membrane protein antibody discovery, with a pipeline of therapeutic antibodies against GPCRs, ion channels, transporters, and immuno-oncology targets. Built on the company’s extensive experience optimizing membrane proteins, this platform enables the isolation, characterization, and engineering of MAbs against otherwise intractable targets. Integral Molecular discovers antibodies for partners in parallel with independent work developing antibodies for licensing. The company currently has therapeutic programs focused on cancer, pain, immunity, and metabolic disorders.

About The Wistar Institute
The Wistar Institute is an international leader in biomedical research with special expertise in cancer and infectious disease research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. wistar.org.

Contacts:
Integral Molecular, Inc.
Benjamin Doranz
President & CEO
215-966-6061
info@integralmolecular.com

The Wistar Institute
Darien Sutton
Media Relations and Communications Manager
215-898-3988

Integral Molecular and Penn Medicine Collaborate on Autoimmune Encephalitis Target Discovery

Integral Molecular is announcing a new collaboration with the Perelman School of Medicine at the University of Pennsylvania (Penn). Integral Molecular and Penn will work together toward discovering new targets that may cause, diagnose, and treat autoimmune encephalitis—a group of conditions that occur when the body’s immune system mistakenly attacks healthy brain cells, causing brain inflammation. Those who suffer from autoimmune encephalitis have symptoms such as short-term memory loss, unexplained seizures, and other psychiatric and neurological symptoms. Integral Molecular will use its Membrane Proteome Array (MPA) platform to identify the targets of autoantibodies derived from patients afflicted with this autoimmune disorder.

“Diagnosing autoimmune disorders is very difficult if we don’t know the targets,” added Benjamin Doranz, President and CEO of Integral Molecular. “Using our breakthrough MPA platform, we have already identified new targets in the immuno-oncology, infectious, and neurodegenerative disease fields, so we expect that this collaboration can have a significant impact in the autoimmunity field for patients.”

The MPA platform contains 5,300 different human membrane proteins, nearly the entire human membrane proteome, each individually expressed in live human cells. In this project, each protein will be screened for antibody binding using unfixed cells and flow cytometry, enabling high-sensitivity detection for discovering new targets that cause autoimmune encephalitis.

“These rare autoimmune disorders are extremely complicated and hard to understand, which makes it a challenge to treat patients with these disorders,” said Eric Lancaster, MD, PhD, an assistant professor of Neurology and director of the Center for Autoimmune Neurology at Penn. “Having a comprehensive understanding of what protein targets underly these devastating disorders, would be valuable and could help clinicians to find more effective diagnostics and therapies.”

Integral Molecular Presents Data on Monoclonal Antibodies (MAbs) Against SLC2A4 (GLUT4), a Critical Target for Diabetes

PHILADELPHIA -(PR NEWSWIRE)- Integral Molecular, the industry leader in discovering antibodies against multipass membrane proteins, recently presented data at the American Diabetes Association’s Annual Meeting on its newly discovered, state-specific antibodies targeting SLC2A4 (GLUT4), a complex glucose transporter. These rare antibodies were discovered using Integral Molecular’s MPS Antibody Discovery platform.

“The SLC2A4 antibodies generated by our MPS Antibody Discovery platform are unique reagents to study glucose uptake in response to insulin,” said Ross Chambers, Vice President of Antibody Discovery. “These results provide additional validation that our platform is optimized to discover high value antibodies for transporters, GPCRs, and other complex membrane proteins.”

In a paper published last year (Tucker et al., May 2018, PNAS), Integral Molecular revealed the discovery of the first functional MAbs against SLC2A4, an insulin-responsive 12-TM transporter involved in diabetes. Functional studies in combination with Shotgun Mutagenesis Epitope Mapping showed MAbs LM043 and LM048 to be state-specific, selectively binding only certain active forms of the SLC2A4 transporter.

Integral Molecular’s MPS Antibody Discovery platform encompasses a comprehensive technology suite that overcomes the obstacles of working with highly conserved and structurally complex membrane protein targets, such as SLC2A4. This suite includes native antigen presentation on Lipoparticles, immunization of divergent species, and the use of B-cell cloning to recover rare antibodies. Integral Molecular is currently isolating MAbs against dozens of membrane protein targets as part of its licensing and discovery partnerships.

About Integral Molecular
Integral Molecular is the industry leader in membrane protein antibody discovery, with a pipeline of therapeutic antibodies against GPCRs, ion channels, transporters, and immuno-oncology targets. Built on the company’s extensive experience optimizing membrane proteins, Integral Molecular’s technology suite enables the isolation, characterization, and engineering of MAbs against otherwise intractable targets. The company currently has therapeutic programs focused on cancer, pain, immunity, and metabolic disorders.

Contact:
Integral Molecular, Inc.
Ross Chambers, PhD, VP of Antibody Discovery
215-966-6061
info@integralmolecular.com
www.integralmolecular.com